At a Glance
- Company: Grail Inc (Nasdaq: GRAL)
- Location: Menlo Park, California
- Headline figures: ~47% stock drop; $904M cash to 2030
- Focus area: Galleri multi-cancer early detection blood test
- Next steps: Full data mid-2026; FDA PMA review ongoing
What happened?
Grail reported on 19 February 2026 that its NHS-Galleri trial, involving over 142,000 UK participants, failed its primary endpoint of statistically significant reduction in Stage III/IV cancer diagnoses. Shares plunged nearly 47% premarket despite Q4 revenue of $43.6M (up 14% YoY) and EPS loss of $2.44 beating estimates. Galleri sales hit 185,000 tests in 2025, driving $136.8M US revenue (up 26%).
Why does it matter?
Galleri detects 50+ cancers via blood DNA methylation; trial miss dents validation for broad screening, critical for FDA PMA/CMS coverage amid $1B+ investment. Positives: 4x overall detection vs standard care, Stage IV trend. Cash runway to 2030 supports PATHFINDER 2 data mid-2026.
Who’s behind it?
Grail, spun from Illumina, leads MCED field. CEO Bob Ragusa stressed “building momentum”; analysts like Morgan Stanley noted high expectations pre-FDA filing.
How was it achieved?
NHS-Galleri added Galleri to standard screening in 50-77-year-olds. Primary miss on late-stage reduction; secondary showed detection gains. FDA PMA modular submission complete Jan 2026.
What’s next?
Extend NHS-Galleri follow-up 6-12 months; present full NHS/PATHFINDER 2 data mid-2026. Expand US sales force; pursue commercial access.
What are people saying?
CEO Ragusa: “Galleri… resulted in a four-fold improvement in overall cancer detection.” Morgan Stanley: “Investors… awaiting readout ahead of FDA/CMS… shares trading meaningfully lower.”